IL263786B - Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation - Google Patents

Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation

Info

Publication number
IL263786B
IL263786B IL263786A IL26378618A IL263786B IL 263786 B IL263786 B IL 263786B IL 263786 A IL263786 A IL 263786A IL 26378618 A IL26378618 A IL 26378618A IL 263786 B IL263786 B IL 263786B
Authority
IL
Israel
Prior art keywords
dimethylbenzofuran
oxadiazol
processes
preparation
benzoic acid
Prior art date
Application number
IL263786A
Other languages
English (en)
Hebrew (he)
Other versions
IL263786A (en
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of IL263786A publication Critical patent/IL263786A/en
Publication of IL263786B publication Critical patent/IL263786B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL263786A 2016-06-22 2018-12-18 Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation IL263786B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610867.2A GB201610867D0 (en) 2016-06-22 2016-06-22 Crystalline forms of a therapeutic compound and processes for their preparation
PCT/EP2017/064802 WO2017220446A1 (en) 2016-06-22 2017-06-16 Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation

Publications (2)

Publication Number Publication Date
IL263786A IL263786A (en) 2019-01-31
IL263786B true IL263786B (en) 2022-05-01

Family

ID=56895172

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263786A IL263786B (en) 2016-06-22 2018-12-18 Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation

Country Status (10)

Country Link
US (2) US10870644B2 (enExample)
EP (1) EP3475274A1 (enExample)
JP (1) JP7102354B2 (enExample)
CN (1) CN109415356B (enExample)
AU (1) AU2017279865B2 (enExample)
CA (1) CA3025858C (enExample)
GB (1) GB201610867D0 (enExample)
IL (1) IL263786B (enExample)
MX (1) MX387013B (enExample)
WO (1) WO2017220446A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
CN111238897B (zh) * 2020-02-18 2023-03-28 上海市皮肤病医院 生物标本的处理方法与处理剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710683B2 (en) 1995-06-07 1999-09-30 Nippon Shinyaku Co. Ltd. Pyrrole derivatives and medicinal composition
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JP3995716B2 (ja) 1996-03-18 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合環含有カルボン酸誘導体
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
EP1025857A4 (en) 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
CN1638776A (zh) * 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
WO2003062230A1 (en) 2002-01-21 2003-07-31 Eisai Co., Ltd. Conbinatorial library of heterocycle compounds
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
DK3549936T3 (da) 2003-04-11 2021-07-12 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP1907347A2 (en) 2005-07-12 2008-04-09 Arcadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
JP2011523997A (ja) 2008-05-30 2011-08-25 フォスター ホイーラー エナージア オサケ ユキチュア 酸素燃焼によって動力を発生させるための方法及び装置
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
EP3233842B1 (en) 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation

Also Published As

Publication number Publication date
WO2017220446A1 (en) 2017-12-28
CA3025858C (en) 2023-09-26
US20210230151A1 (en) 2021-07-29
MX387013B (es) 2025-03-19
CN109415356B (zh) 2022-03-08
US11584741B2 (en) 2023-02-21
AU2017279865A1 (en) 2019-01-03
EP3475274A1 (en) 2019-05-01
GB201610867D0 (en) 2016-08-03
MX2018016250A (es) 2019-08-29
AU2017279865B2 (en) 2020-11-26
JP7102354B2 (ja) 2022-07-19
CA3025858A1 (en) 2017-12-28
IL263786A (en) 2019-01-31
CN109415356A (zh) 2019-03-01
US20190345147A1 (en) 2019-11-14
US10870644B2 (en) 2020-12-22
JP2019522650A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
HUE058274T2 (hu) 1,2,4-oxadiazol és tiadiazol-vegyületek, mint immunmodulátorok
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
IL256237B (en) Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid
HUE039869T2 (hu) N-Azaspirocikloalkán helyettesített N-heteroaril vegyületek és készítmények az SHP2 aktivitás gátlására
HUE056583T2 (hu) 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái
ZA201606386B (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
IL247653A0 (en) Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole
PL3207928T3 (pl) Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych
SG11201707384YA (en) Crystal of 3,5-disubstituted benzene alkynyl compound
IL273896A (en) Crystal forms of 3-disubstituted 1, 2, 4-oxadiazole
IL263786B (en) Crystalline forms of 4-(5-(7,4-dimethylbenzofuran-2-yl)-4,2,1-oxadiazol-3-yl)benzoic acid and processes for their preparation
EP3262039A4 (en) Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
IL253239A0 (en) Method for preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[5,4[b-pyridin-2-yl)pyridin-2-amine
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
PT2943488T (pt) Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
IL249248A0 (en) Non-aqueous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-2,1-benzaisoxazole
LT3212644T (lt) 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-ilacetamido dariniai, kurie yra naudotini diabeto gydymui
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
SI3143019T1 (sl) Kristalna oblika 6-((4R)-4-metil-1,2-dioksido-1,2,6-tiadiazinan-2-IL)isokvinolin-1- karbonitrila
IL263299A (en) Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
TH1601000138A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
HK1233637A1 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
HK1233636A1 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation